InvestorsHub Logo
icon url

stocksrising

06/03/24 8:44 AM

#18 RE: jondoeuk #17

Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
icon url

Monksdream

06/03/24 1:25 PM

#19 RE: jondoeuk #17

CRBU new 52 week low
icon url

jondoeuk

06/03/24 9:17 PM

#21 RE: jondoeuk #17

Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
icon url

NY1972

06/14/24 9:28 PM

#23 RE: jondoeuk #17

Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase